<DOC>
	<DOCNO>NCT00279032</DOCNO>
	<brief_summary>The finding preclinical animal model confirm peripheral anti-inflammatory/analgesic activity GW406381 also suggest contribution central site action anti-hyperalgesic efficacy may share COX-2 inhibitor . A central action consistent distribution GW406381 CNS animal . Furthermore , preliminary data positron emission tomography study 6 healthy male volunteer receive tracer dose 11C label GW406381 indicate GW406381 rapidly absorb central nervous system man .</brief_summary>
	<brief_title>GW406381 In Patients With Peripheral Nerve Injury</brief_title>
	<detailed_description />
	<mesh_term>Hyperalgesia</mesh_term>
	<mesh_term>Peripheral Nerve Injuries</mesh_term>
	<criteria>Inclusion criterion : Baseline average daily Pain Score great equal 4 ( average 7 day prior Treatment Visit 1 ) , report 11 point pain intensity numerical rating scale . Subjects medication neuropathic pain received nerve block neuropathic pain . Exclusion criterion : Known history hypersensitivity intolerance acetaminophen , paracetamol , aspirin , COX2 inhibitor NSAIDs . Subject unable discontinue NSAIDs COX2 inhibitor ( except aspirin cardioprotective ; certain dos apply ) , topical lidocaine topical capsaicin treatment pain period prior randomization duration study . Subject unable refrain sedative use study ( benzodiazepine prescribe hypnotic sleep agent allow ) . Subject unable refrain nerve block 4 week prior randomisation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>GW406381</keyword>
	<keyword>peripheral nerve injury</keyword>
	<keyword>patient</keyword>
	<keyword>allodynia</keyword>
	<keyword>hyperalgesia</keyword>
	<keyword>randomise</keyword>
	<keyword>placebo-controlled</keyword>
</DOC>